Drug Search Results
More Filters [+]

Kanamycin

Alternative Names: kanamycin, kantrex, klebcil
Latest Update: 2023-09-28
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 30S Ribosomal Subunit Inhibitor,Protein Synthesis Inhibitor,16S Ribosomal RNA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular,Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Bangladesh | Bulgaria | Chile | China | Colombia | Czech | Dominican Republic | Germany | Hong Kong | India | Indonesia | Ireland | Italy | Korea | Latvia | Lithuania | Malaysia | Malta | Morocco | New Zealand | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Singapore | Slovakia | South Africa | Taiwan | Thailand | Turkey | Ukraine | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Julio Ramirez
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Kanamycin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Osteomyelitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BCH_PPK003

N/A

Recruiting

Tuberculosis

2026-10-01

PRESTO:Osteo

P1

Terminated

Osteomyelitis

2018-11-07

Recent News Events

Date

Type

Title